PTYLTD
    • Free Reports
  • Pricing
  • About us
  • Contact us
  • Login | Sign up
PTYLTD

Free Reports

Pricing

About us

Contact us

  • Home
  • Insights into ASX Stocks
  • By Topic
  • Insights From Technical Analysis

Insights From Technical Analysis

Tivan (ASX: TVN)

Has Tivan (ASX: TVN) Formed a Sustainable Long-Term Floor?

Jun 3, 2026
Proactive Equities Team

Tivan (ASX: TVN) develops critical minerals across Australia and Timor-Leste, led by the Speewah Fluorite project. Following a post-feasibility sell-off and rising cash burn, the stock faces a neutral-to-bearish technical outlook ahead of its late-2026 Final Investment Decision.

Tamboran Resources Corporation (ASX: TBN)

Is Tamboran Resources Corporation (ASX: TBN) Uptrend Still Intact Following Its Pullback to Support?

Jun 1, 2026
Proactive Equities Team

Tamboran Resources is a pre-production shale gas developer in the Beetaloo Basin, advancing toward first gas in 2026. Strong drilling results, contracts, and infrastructure progress support its uptrend, though risks remain around execution, funding, and market access beyond initial supply agreements.

Australian Mines (ASX: AUZ)

Can Australian Mines (ASX: AUZ) Hold Its Breakout and Target Higher Levels?

Jun 1, 2026
Proactive Equities Team

Australian Mines (ASX: AUZ) is a critical minerals explorer focused on battery metals, rare earths, and gold across Australia and Brazil, advancing projects like Sconi and Flemington while leveraging strong commodity trends and strategic funding to drive its 2026 share price recovery.

Telix Pharmaceuticals (ASX: TLX)

Telix Pharmaceuticals (ASX: TLX) Rebounds From Heavy Sell-Off Reignites Investor Optimism

Jun 1, 2026
Proactive Equities Team

Telix Pharmaceuticals (ASX: TLX) is recovering after a sharp biotech sell-off driven by regulatory and legal concerns. Renewed investor confidence follows strong revenue growth, progress in Phase 3, and a Regeneron partnership, with FY2026 revenue nearing US$1 billion and pipeline milestones advancing.

Neuren Pharmaceuticals (ASX: NEU)

Is Neuren Pharmaceuticals (ASX: NEU) Poised to Reclaim Higher Levels After Forming a Higher Low?

May 28, 2026
Proactive Equities Team

Neuren Pharmaceuticals (ASX: NEU) is a rare-disease biotech generating revenue from DAYBUE while advancing NNZ-2591. After declines from regulatory and guidance setbacks, improving US rollout and technical strength suggest a recovery, with the stock forming higher lows and testing key resistance levels.

Marmota (ASX: MEU)

Marmota (ASX: MEU) Share Price Surges as Traders Chase Momentum in South Australia Gold Play

May 28, 2026
Proactive Equities Team

Marmota (ASX: MEU) has surged back into focus after strong gains driven by high-grade drilling results from its Greenewood gold project in South Australia. Renewed exploration activity, rising gold prices, and aggressive drilling have boosted investor interest. The stock remains highly speculative but increasingly watched by ASX momentum traders.

 

Proactive Equities

At Proactive Equities, we combine deep market expertise with rigorous analysis to deliver stock recommendations you can trust. Our team of seasoned analysts continuously monitor global markets, economic trends, and company fundamentals to identify high-potential investment and trade opportunities.

Company

Home
Pricing
Contact Us
About Us

Resources

ASX Insights
Investing Basics

Links

Privacy Policy
Terms and Conditions
Product Disclosure Statement

Proactive Equities Pty Ltd (ACN: 687 232 471) is a Corporate Authorised Representative (AFSR No. 001318293) of Australia National Investment Group Pty Ltd (ABN: 40 636 343 630), which holds an Australian Financial Services Licence (AFSL no. 522028). The information on this website is general information only and does not constitute personal financial advice. We have not taken the individual circumstances, financial objectives or needs of any investor into account when preparing this information. Investors should consider their circumstances and the relevant PDS for any investment and obtain professional financial and tax advice before making any investment decision. The information on this website is not a recommendation to make any investment or to adopt any particular investment strategy. You should make your own professional assessment of the suitability of this information, relying on your own inquiries. Investments in securities are subject to investment risk. Investment value may go down as wellas up, and investors may not get back the full amount originally invested. Risks include: the investment objective may not be achieved, share market and other market risk, liquidity risk, and currency risk with international investments. Any past performance shown is not an indication of future performance. Commission and other costs charged by executing broker are not considered when calculating past performance. To the extent permitted by law Proactive Equities Pty Ltd accepts no liability for any errors or omissions in, or loss from reliance on the information in this website.

12345...20
Page 3 of 20